Summary

The Middle East & Africa insulin delivery device market reflects a shifting healthcare landscape characterised by increased diabetes prevalence, technological improvements, and the quest for better patient outcomes. The Middle East & Africa region has substantial problems controlling diabetes while embracing the potential for innovation in insulin delivery technologies, albeit spanning a varied territory with varying healthcare infrastructures and cultural peculiarities. The Middle East & Africa region is experiencing a significant increase in diabetes incidence, following global trends. According to the International Diabetes Federation (IDF), diabetes is prevalent across the Middle East and portions of Africa, owing to causes such as increasing urbanisation, sedentary lifestyles, genetic susceptibility, and dietary changes. This prevalence throws enormous strain on healthcare systems that are attempting to manage and mitigate the consequences of this chronic condition. The Middle East & African region's healthcare systems are diverse, ranging from well-established infrastructure in some parts to inadequate access and resources in others. Variations in healthcare accessibility, regulatory frameworks, and pricing lead to variances in insulin delivery device adoption throughout the region's countries. Economic constraints, healthcare policies, and cultural preferences all have an impact on market dynamics and device accessibility. The Middle East & Africa's insulin delivery device market is being driven by reasons such as an ageing population, a lower incidence rate of diabetes among the population, expanding government activities to combat diabetes, and more awareness among diabetes patients. Type 1 diabetes is common in the Middle East & Africa, and these individuals require lifelong insulin to keep the glucose level in their blood in a safe range. For these people, an automated insulin delivery device is being developed. Insulin delivery systems give insulin every 5 minutes or at the specified time. Diabetes patients use these devices to improve their overall health.

According to the research report, "Middle East & Africa Insulin Delivery Devices Market Outlook, 2028," published by Bonafide Research, the Middle East & Africa Insulin Delivery Devices market is anticipated to grow at a 5% CAGR by 2023–28. Increases in obesity incidence and people living unhealthy lifestyles are expected to drive the Middle East & Africa insulin delivery device market. The primary cause of the increased glucose level in the body is an increase in unhealthy foods such as junk food, soft drinks with high sugar content, and a lack of exercise. This variation in glucose level can occur at any age, and these people must take insulin to avoid a rapid collapse and risk in their lives. Technological advancements and manufacturers increasing efforts to create improved and cost-effective insulin delivery systems are expected to have a favourable impact on market growth in the Middle East & Africa region. The Middle East & African region is experiencing a substantial and increasing diabetes epidemic, with a greater prevalence than in many other parts of the world. Rapid urbanisation, nutritional changes, genetic susceptibility, and lifestyle changes all contribute to this increase. The region's large number of diabetes cases highlights the critical need for effective, accessible, and improved insulin delivery devices. The adoption of insulin delivery devices is influenced by economic differences and differing degrees of healthcare accessibility within the Middle East & Africa region. Affordability, insurance coverage, and accessibility to healthcare services all have a substantial impact on the uptake of these devices among various demographics in the region. The Middle East & Africa region has distinct illness patterns, including a greater incidence of various diabetes-related comorbidities than other regions. Addressing these individual problems, including comorbidities, cultural food habits, and genetic predispositions, influences the design and adoption of insulin delivery systems customised to these complications. Climate and environmental variables in some parts of the Middle East & Africa region make insulin storage and use difficult. Extreme temperatures and environmental factors can have an impact on insulin stability and efficacy. Insulin delivery systems that accommodate these environmental constraints, such as temperature-resistant designs, gain importance in these places.

Based on country market is bifurcated into three major countries United Arab Emirates, Saudi Arabia and South Africa. Saudi Arabia is expected to lead the Middle East & Africa insulin delivery devices market.

The demand for and use of insulin delivery devices has increased significantly in Saudi Arabia's healthcare environment, reflecting the country's growing emphasis on diabetes control. As the global prevalence of diabetes climbs, Saudi Arabia is at the forefront of combating this chronic disease that affects millions of Saudis. Diabetes is on the rise in Saudi Arabia, with an alarming increase in the number of people diagnosed with the disease. Sedentary behaviour, poor diet, and genetic predispositions are all significant causes of the increased diabetes incidence. As a result, the demand for effective diabetes care solutions, such as insulin delivery devices, has increased throughout the country. The Saudi government recognises diabetes as a public health issue and has taken aggressive initiatives to improve healthcare infrastructure and services. Over the next decade, Saudi Arabia hopes to reduce diabetes prevalence by 10%. In order to counteract this disease, the government is taking many actions, including taxing sugary drinks, focusing on fitness programmes, and focusing on preventative therapy. The Saudi Arabian insulin delivery device market is growing as a result of the government's emphasis on diabetes control and the country's increasing purchasing power. The rising urbanisation and lifestyle changes in Saudi Arabia have largely contributed to the rise in diabetes prevalence. This health issue has been exacerbated by sedentary lifestyles, bad dietary habits, and genetic predispositions. The Saudi government has prioritised fighting the diabetes epidemic through a variety of healthcare interventions. The government has implemented nationwide diabetes prevention, management, and treatment measures, including increased access to critical medications like insulin and fostering advances in diabetes care technologies.

In terms of product market is divided into insulin pens, insulin pumps, insulin pen needles, insulin syringes and others insulin delivery devices (insulin transdermal patches, insulin inhalers, insulin jet injection). Insulin pumps are gaining significant traction in Middle East & Africa insulin delivery devices market.

Insulin pump technology has evolved, making these devices more user-friendly, precise, and responsive to changing patient needs. Patients seeking more complex and efficient diabetes care solutions are drawn to continual developments such as automated insulin delivery, integrated continuous glucose monitoring (CGM), and user-friendly interfaces. In comparison to older injectable methods, insulin pumps provide more precise insulin delivery, allowing for more accurate glycemic control. This precision reduces blood sugar oscillations, lowering the risk of both hyperglycemia and hypoglycemia. Better control aids in the prevention of long-term diabetes problems such as neuropathy and cardiovascular difficulties. Insulin pumps are convenient and flexible appeal to individuals seeking a more adaptive approach to diabetes control. Pumps allow you to alter insulin dosages based on mealtime fluctuations, physical activity, and individual insulin requirements, allowing you to live a more flexible lifestyle while maintaining treatment efficacy. Insulin pumps offer a great level of personalisation, allowing patients and healthcare practitioners to adapt insulin delivery to specific needs. This component of customization, which includes changeable basal rates and bolus dose options, is consistent with the trend towards personalised medicine, which improves patient satisfaction and treatment outcomes.

Based on end user market is bifurcated into home care, hospitals and clinics and others. Hospitals and clinics are one of major end users of insulin delivery devices in Middle East & African region Based on indication market is segmented into diabetes, pregnancy, cardiovascular disorders & hypertension, respiratory diseases, hearing disorders, cancer, movement disorders, wound care and other indications (sleep disorders, kidney disorders, neurovascular diseases, and HIV).

Hospitals and clinics frequently act as specialised diabetes care centres, offering full services for diabetes diagnosis, treatment, and management. These facilities serve a large number of patients who require specialist diabetes care and assistance. Hospitals and clinics provide both inpatient and outpatient services to a wide range of diabetic patients. Diabetes inpatients benefit from hospital treatment, especially those who require intense insulin administration or are having acute complications. Meanwhile, outpatient services are available to anyone who needs normal diabetes control. Advanced insulin delivery devices are available at healthcare facilities such as hospitals and clinics. They act as hubs for cutting-edge medical technology, providing patients with a selection of insulin pens, pumps, continuous glucose monitoring systems, and other novel solutions. Diabetes is an established risk factor for cardiovascular disease and high blood pressure. The Middle East & Africa region has a huge diabetes burden, with a large number of people affected by the disease. Diabetes prevalence in the region is increasing, as is the incidence of associated cardiovascular problems. Diabetes frequently coexists with cardiovascular disease and hypertension. Diabetes patients are more likely to have cardiovascular issues such as heart disease, stroke, and hypertension. As these disorders interact, a complete strategy for healthcare management is required, including the incorporation of insulin delivery devices. Continuous glucose monitoring systems and smart insulin pumps, for example, are advanced insulin delivery devices with integrated features that enable better diabetes monitoring and treatment. These systems provide real-time data, allowing for the early detection and management of fluctuations in blood sugar levels, which can impact cardiovascular health.

Companies Covered in this report:
Novo Nordisk A/S , Sanofi S.A., Medtronic plc, Becton, Dickinson and Company, Insulet Corporation, Biocon Limited , Wockhardt Ltd., B. Braun Melsungen AG.


Considered in this report:

• Geography: Middle East & Africa
• Historic year: 2017
• Base year: 2022
• Estimated year: 2023
• Forecast year: 2028

Aspects covered in this report:

• Middle East & Africa Insulin Delivery Devices market Outlook with its value and forecast along with its segments
• Country-wise Insulin Delivery Devices market analysis
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

Country covered in the report:

• United Arab Emirates
• Saudi Arabia
• South Africa

By Product:

• Insulin Pens
• Insulin Pumps
• Insulin Pen Needles
• Insulin Syringes
• Others Insulin Delivery Devices(Insulin transdermal patches, Insulin inhalers, Insulin jet injection)

By End User:

• Home Care
• Hospitals & Clinics
• Others

By Indication:

• Diabetes
• Pregnancy
• Cardiovascular Disorders & Hypertension
• Respiratory Diseases
• Hearing Disorders
• Cancer
• Movement Disorders
• Wound Care
• Other Indications (sleep disorders, kidney disorders, neurovascular diseases, and HIV)

The approach of the report:

This report consists of a combined approach of primary and secondary research. Initially, secondary research was used to get an understanding of the market and list the companies that are present in it. The secondary research consists of third-party sources such as press releases, annual reports of companies, and government-generated reports and databases. After gathering the data from secondary sources, primary research was conducted by conducting telephone interviews with the leading players about how the market is functioning and then conducting trade calls with dealers and distributors of the market. Post this; we have started making primary calls to consumers by equally segmenting them in regional aspects, tier aspects, age group, and gender. Once we have primary data with us, we can start verifying the details obtained from secondary sources.

Intended audience:

This report can be useful to industry consultants, manufacturers, suppliers, associations, and organisations related to the Insulin Delivery Devices industry, government bodies, and other stakeholders to align their market-centric strategies. In addition to marketing and presentations, it will also increase competitive knowledge about the industry.




***Please Note: It will take 48 hours (2 Business days) for delivery of the report upon order confirmation.

ページTOPに戻る

Table of Contents